Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma.

Saved in:
Bibliographic Details
Title: Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma.
Authors: Sternschuss M; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel., Toumbacaris N; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA., Das JP; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA., Powles T; Barts Cancer Institute Biomedical Research Center, Queen Mary University of London, London, UK., Kotecha RR; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA., Laccetti AL; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA., Xiao H; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA., Feld E; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA., McHugh DJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA., Keegan NM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA., Bajorin DF; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA., Funt SA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA., Shah NJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA., Iyer G; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA., Aggen DH; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA., Teo MY; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA., Ostrovnaya I; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA., Rosenberg JE; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address: rosenbj1@mskcc.org.
Source: ESMO open [ESMO Open] 2025 Jun; Vol. 10 (6), pp. 105305. Date of Electronic Publication: 2025 Jun 05.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2059-7029
DOI:10.1016/j.esmoop.2025.105305